In cluster 1, which shows a mesenchymal phenotype with glycolytic Warburg metabolism and lactate export, the MCT1 inhibitor (AZD3965) in combination with ICI increases ICI activity, reducing tumor efflux of lactate (35) and decreasing lactate uptake by Tregs (56, 57). This evidence concerns the gene SLC16A1 and neoplasm.